However, androgen-deprivation therapies cannot completely abolish AR signaling and most prostate cancers become eventually castration-resistant prostate cancer (CRPC), because of the occurence of AR gene point mutations or truncation [6]. The gene discussed is AR; the disease is prostate carcinoma.